HIRA

Cosmo and Hyundai Pharm Announce Signing of License Agreement for Winlevi® in Korea

Retrieved on: 
Jeudi, juin 22, 2023
National health insurance, Male, Partnership, Androgen, IQVIA, Pharming, Quality of life, XETRA, Clascoterone, Hira, Sun Pharma, Acne, Prescription, Incidence, Spironolactone, C43, Hyundai, Patient, Physician, South Korea, Health Insurance Review and Assessment Service, License, Ageing, FDA, Skin, HIRA, Female, Pharmaceutical industry, Cassiopea

Dublin, Ireland & Seoul, Korea – 22 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyundai Pharmaceutical Co., Ltd. (“Hyundai Pharm”) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in the Republic of Korea.

Key Points: 
  • Dublin, Ireland & Seoul, Korea – 22 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyundai Pharmaceutical Co., Ltd. (“Hyundai Pharm”) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in the Republic of Korea.
  • Under the terms of the agreement, Hyundai Pharm will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi® in the Republic of Korea.
  • With this license agreement, Hyundai Pharm aims to address this unmet medical need by offering a new treatment option for both male and female acne patients in South Korea.
  • SangJoon Lee, Chief Executive Officer of Hyundai Pharm, said “We are delighted to establish a strategic partnership through the licensing agreement with Cosmo and its subsidiary, Cassiopea.

HIRA’s International Cooperation Efforts to Achieve Universal Health Coverage for All

Retrieved on: 
Lundi, février 7, 2022
Technology, Insurance, Infectious Diseases, Other Technology, Professional Services, Other Health, Training, General Health, Health, Education, Health Insurance Review and Assessment Service, HIRA, Universal health care, Ministry, UHC, National health insurance, Welfare, Review, ICT, Ministry of Health and Welfare (South Korea), Social Security, Partnership, World Health Organization, Kingdom, Public health, WHO, Medal of Honor (video game series), Pharmaceutical industry, Health, ASEAN

Based on its medical expertise and state-of-the-art ICT capacity, HIRA is working closely with a number of international organizations towards the global achievement of Universal Health Coverage (UHC) for all.

Key Points: 
  • Based on its medical expertise and state-of-the-art ICT capacity, HIRA is working closely with a number of international organizations towards the global achievement of Universal Health Coverage (UHC) for all.
  • In 2021, the Ministry of Health and Welfare of Korea (MoHW) and HIRA launched the K-Health International Cooperation Strategy project in order to strengthen collaboration with health sectors in the ASEAN region.
  • In addition, HIRA was acknowledged for its Strategic Purchasing for Sustainable National Health Insurance and designated as a World Health Organization (WHO) Collaborating Center with a four-year term.
  • Upon the designation, HIRA is preparing for capacity building programs and international training courses in partnership with WHO.